Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
46 Results for "
229E
" in MedChemExpress (MCE) Product Catalog:
Products (46)
46 Results for "229E" in MCE Product Catalog:
153
153 Publications Verification
Category:
Infection Terpenoids Diterpenoids Plants Umbelliferae Disease Research Fields Cancer Thapsia garganica L.
Target:
6
6 Cited Publications
Vps34-IN-2 is a novel, potent and selective inhibitor of Vps34 with IC50s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively . Vps34-IN-2 shows antiviral activity against SARS-CoV-2 (IC50 of 3.1 μM), HCoV-229E (IC50 of 0.7 μM) and HCoV-OC43 .
3
3 Cited Publications
Synonyms: Hexamethylene amiloride; HMA
Target:
5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) derives from an amiloride and is a potent Na +/H + exchanger inhibitor, which decreases the intracellular pH (pHi) and induces apoptosis in leukemic cells. 5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) is also an inhibitor of the HIV-1 Vpu virus ion channel and inhibits mouse hepatitis virus (MHV) replication and human coronavirus 229E (HCoV229E) replication in cultured L929 cells with EC50s of 3.91 μM and 1.34 μM, respectively .
1
1 Cited Publications
Cat. No.: HY-136149A
Purity: 99.96%
Target:
Research Areas:
Mpro inhibitor N3 hemihydrate is a potent inhibitor of SARS-CoV-2 Mpro with an EC50 of 16.77 μM for SARS-CoV-2. Mpro inhibitor N3 hemihydrate specifically inhibits Mpro from multiple coronaviruses, including SARS-CoV and MERS-CoV. Mpro inhibitor N3 hemihydrate displays inhibition against HCoV-229E, FIPV, and MHV-A59 with individual IC50 of 4.0 μM, 8.8 μM, and 2.7 μM, respectively .
Cat. No.: HY-NP229
Cat. No.: HY-L229
159 compounds
Kidneys are one of the vital organs in the human body. Due to their exposure to higher concentrations of circulating drugs or metabolites, they are highly susceptible to drug-induced renal injury (DIRI). According to statistics, drug-induced kidney injury accounts for approximately 20% of nephrotoxicity reports and can lead to acute kidney injury (AKI), chronic kidney disease (CKD), or even end-stage renal disease (ESRD). Early detection of drug nephrotoxicity is crucial for preventing irreversible kidney damage. Research into its mechanisms can help optimize clinical medication by adjusting dosages or avoiding combinations of nephrotoxic drugs. Additionally, predicting drug-induced nephrotoxicity in early drug development can reduce the risk of late-stage R&D failure.
MCE offers 159 nephrotoxicity compounds that have been clearly reported by the FDA to be associated with kidney injury. This library can be used for studying molecular mechanisms of nephrotoxicity or developing novel biomarkers.
Target:
Research Areas:
Mpro inhibitor N3 is a potent SARS-CoV-2 MPro inhibitor with an EC50 value of 16.77 µM. Mpro inhibitor N3 shows antiviral activities against HCoV-229E, FIPV, IBV and MHV-A59 .
Synonyms: EDP-235
Target:
Research Areas:
Zevotrelvir (EDP-235) is a coronavirus inhibitor that can inhibit 229E hCoV and the SARS-CoV-2 3C-like (3CL) protease (IC50 <0.1 mM). Zevotrelvir can be used in research on coronavirus infections .
Cat. No.: HY-169092
CAS No.: 3041047-51-9
Target:
Research Areas:
PF-07957472 (Compound 4) is an orally active and selective SARS-CoV-2 papain-like protease (PLpro) inhibitor, with a Ki of 2 nM against SARS-CoV-2 PLpro. PF-07957472 reduces SARS-CoV-2 viral titers in the lungs of infected mice and inhibits SARS-CoV-2-induced cytopathic effects in cells. PF-07957472 can be used for the research of COVID-19 .
Category:
Cat. No.: HY-177303
CAS No.: 717104-43-3
Research Areas:
AXT-914 is a Calcium-sensing receptor (CaSR) inhibitor. AXT-914 has antiviral activity against the coronavirus HCoV 229E and SARS-CoV2. AXT914 reduces cytosolic calcium signalling activity of CaSR mutations. AXT-914 can be used for Bartter syndrome type 5 and autosomal dominant hypocalcemia (ADH) and coronavirus infections research .
Cat. No.: HY-161356
CAS No.: 1345406-09-8
Target:
Research Areas:
BPR3P0128 is an orally active, non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor that has been shown to inhibit the activity of various SARS-CoV-2 variants. The EC50 for SARS-CoV-2 and HCoV-229E are 0.62 μM and 0.14 μM. BPR3P0128 demonstrates effective anti-pancoronavirus activity within the submicromolar range. PR3P0128 shows synergistic antiviral activity when combined with Remdesivir (HY-104077) .
Cat. No.: HY-170524
CAS No.: 3052313-73-9
Research Areas:
TDI-015051 is a highly selective, orally active antiviral agent that targets the coronavirus NSP14 guanine-N7 methyltransferase. TDI-015051 binds to substrates in a non-competitive manner and forms a stable ternary complex, precisely blocking the capping and methylation processes of viral mRNA. TDI-015051 potently inhibits a variety of coronaviruses (including SARS-CoV-2 and MERS). By impairing viral replication and translation and inducing a moderate type I interferon-mediated immune response, it significantly reduces pulmonary viral load and exhibits a synergistic effect with Nirmatrelvir (HY-138687). In addition, TDI-015051 does not inhibit non-coronavirus methyltransferases, and the drug-resistant mutations it induces impair viral fitness, demonstrating excellent antiviral properties and safety. TDI-015051 can be used for research on COVID-19 and the replication mechanism of coronaviruses .The IC50 values of TDI-015051 against SARS-CoV-2, α-hCoV-NL63, α-hCoV-229E, β-hCoV-MERS are 0.15 nM, 1.7 nM, 2.6 nM and 3.6 nM, respectively, and the Ka value against SARS-CoV-2 is 0.061 nM .
Cat. No.: HY-122668
CAS No.: 2141978-86-9
Target:
Research Areas:
K22 is an anti-Coronaviral compound. K22 reduces double-stranded RNA. K22 displays antiviral activity beyond the Coronavirinae subfamily, namely against nidoviruses of the Torovirinae subfamily (EToV and WBV) and members of the Arteriviridae family (PRRSV, EAV). K22 displays antiviral activity against HCoV-229E .
Cat. No.: HY-170799
CAS No.: 2127358-36-3
Target:
Research Areas:
HNC-1664 is the orally active inhibitor for RNA-dependent RNA polymerase (RdRP). HNC-1664 exhibits broad-spectrum antiviral activity against coronavirus (SARS-CoV-2 wildtype and its mutants XBB.1.18, HK.3.1, BF.7.14, BA.1HCoV-229E, HCoV-OC43) and arenavirus. HNC-1664 exhibits anti-infectious activity in SARS-CoV-2 Delta infected mouse models .
Cat. No.: HY-175029
CAS No.: 2892287-29-3
Target:
Research Areas:
ALG-097558 is an orally active 3CLpro inhibitor. ALG-097558 demonstrates pan-coronavirus activity against various SARS-CoV-2 variants as well as other human coronaviruses (HCoVs) such as SARS-CoV-1, α-HCoV 229E, and β-HCoV OC43. ALG-097558 demonstrates potent inhibition with IC50s of 2 nM (SARS-CoV-2 3CLpro) and 6 nM (229E 3CLpro). ALG-097558 demonstrates antiviral activity in the SARS-CoV-2 hamster infection model. ALG-097558 can be used for the study of viral infections[1].
HCoV-229E-IN-1 is a potent inhibitor of HCoV-229E replication, with an EC50 of 0.65 μM and 0.6 μM in MTS and CPE cells, respectively .
SARS-CoV-2 3CLpro-IN-13 is a potent SARS-CoV-2 3CL protease inhibitor with an IC50 value of 21 nM. SARS-CoV-2 3CLpro-IN-13 shows anti-coronavirus activity .
Cat. No.: HY-169410
Target:
Research Areas:
3CLPro-IN-3 (Compound A36) is an inhibitor for SARS-CoV-2 3CLpro with IC50 of 51.3 nM. 3CLPro-IN-3 exhibits antiviral activity against human coronavirus 229E, OC43 and mouse hepatitis virus MHV .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
